Video
Dr. Zhang on risk stratification and treatment selection in mCSPC
Author(s):
Video Player is loading.
Jingsong Zhang, MD, PhD, discusses contributing factors to risk stratification and subsequent treatment selection in patients with metastatic castration-sensitive prostate cancer. The factors Zhang highlights include site of metastases, PSA response, and metastases burden.
Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.
Related Videos
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Related Content
